Immune checkpoint inhibitors and cardiovascular toxicity
Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG
Curr Med Chem. 2018;25(11):1327-1339
Cardiotoxicity induced by anti-neoplastic drugs remains a critical issue, particularly after treatment with anthracyclines, but even targeted therapies and biological molecules can induce reversible and irreversible cardiac dysfunction.
Immune checkpoint inhibitors such as Ipilimumab (anti-CTLA-4) as well as the newly developed blocking monoclonal antibodies targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab, durvalumab, avelumab, and BMS-946559) are associated with a wide spectrum of immune-related adverse events, but their link to cardiac toxicity has been underestimated despite reports of fatal heart failure following treatment with checkpoint inhibitors.
© All Rights Reserved